For our 75th anniversary, we sat down with Dana-Farber leaders, past and present, to gather their reflections on the evolution of the Institute and its culture, their careers, and their expectations for the future. Sara Tolaney, MD, MPH, Chief of the Division of Oncology at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the exciting development of treatments for early stage HER2+ breast cancer and how this has shaped the way we practice.

Watch the entire series here: [ Ссылка ]

свернуть